Availability

  • Request Lead Time
  • In stock and ready for quick dispatch
  • Usually dispatched within 3-7 working days.
Shipping Destination:
United States
Shipping charges:
Freight/Packing: $34.00

Need Help?

Ask a Question Support@biorbyt.com
Product Overview
Product Name CD133 antibody
Catalog Number orb99113
Species/HostRabbit
ReactivityHuman, Mouse, Rat
ConjugationUnconjugated
Custom conjugations
Tested applicationsELISA, ICC, IF, IHC-P, WB
Immunogen

KLH conjugated synthetic peptide derived from human CD133. Please contact us for the exact immunogen sequence. The peptide is available as orb374954.

Target CD133. Human;Mouse;Rat. No cross reactivity with other proteins.
Alternative Names
Product Properties
Form/Appearance 10 mM PBS, 0.02% sodium azide, 10 mg/ml BSA
Concentration

- 100 μg (in 100 μl): 1 mg/ml
- 200 μg (in 200 μl): 1 mg/ml

Storage After reconstitution store at 4°C.for up to two weeks. For long term storage, aliquot and store at -20°C. Avoid freeze/thaw cycles.
Note For research use only.
Isotype IgG
ClonalityPolyclonal
Purity

Polyclonal antibodies are purified by peptide affinity chromatography

MW 95 kDa
Uniprot ID

O43490 (Human); O54990 (Mouse)

NCBI NP_001139319.11; NM_001145847.11
Entrez 8842
Product Description

Rabbit polyclonal antibody to CD133, which is also known as prominin or AC133. CD133 is a marker frequently found on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells.

Application Notes
Dilution Range IHC-P:1:200, WB: 1:500, IF/ICC: 1:200
Application Notes Several IHC experiments have been done on human cancer tissue. Please review the information on the product page under "Additional Information"

Experiment Notes: Add 0.2 ml of distilled water will yield a concentration of 500 ug/ml.
Validation Images
IHC-P analysis of mouse kidney tissue using CD133 antibody (Primary antibody diluted to 1:200)
IHC-P analysis of mouse kidney tissue using CD133 antibody (Primary antibody diluted to 1:200)
IF analysis of mouse skin tissue using CD133 antibody (Dilution of primary antibody 1:200)
IF analysis of mouse skin tissue using CD133 antibody (Dilution of primary antibody 1:200)
IHC-P image of human endometrial cancer tissue using anti-CD206 (dilution of primary antibody at 1:100)
IHC-P image of human endometrial cancer tissue using anti-CD206 (dilution of primary antibody at 1:100)
Immunohistochemical staining of paraffin embedded human endometrial cancer tissue using anti-CD206 (primary antibody at 1:200)
Immunohistochemical staining of paraffin embedded human endometrial cancer tissue using anti-CD206 (primary antibody at 1:200)
Western blot analysis of Mouse large intestine (Lane 1), Mouse spinal cord (Lane 2) using CD133 antibody (Dilution of primary antibody 1:200)
Western blot analysis of Mouse large intestine (Lane 1), Mouse spinal cord (Lane 2) using CD133 antibody (Dilution of primary antibody 1:200)
IHC-P image of human breast cancer tissue using anti-CD206 (dilution of primary antibody at 1:100)
IHC-P image of human breast cancer tissue using anti-CD206 (dilution of primary antibody at 1:100)
Immunohistochemical staining of human mammary fibroma tissue using anti-CD206 (dilution of primary antibody - 1:100)
Immunohistochemical staining of human mammary fibroma tissue using anti-CD206 (dilution of primary antibody - 1:100)
Western blot analysis of rat small intestine tissue using CD133 antibody (dilution at 1:200-1:1000 based on 1mg/mL)
Western blot analysis of rat small intestine tissue using CD133 antibody (dilution at 1:200-1:1000 based on 1mg/mL)
Western blot analysis of human muscle (Lane1), Rat muscle (Lane2), Rat bladder (Lane3) using CD133 antibody (Dilution at: 1:500)
Western blot analysis of human muscle (Lane1), Rat muscle (Lane2), Rat bladder (Lane3) using CD133 antibody (Dilution at: 1:500)
IHC-P analysis of human colonic adenocarcinoma tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of human colonic adenocarcinoma tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of human muscle tissue using CD133 antibody (Primary antibody diluted to 1:100)
IHC-P analysis of human muscle tissue using CD133 antibody (Primary antibody diluted to 1:100)
IHC-P analysis of human lung cancer tissue using CD133 antibody (Primary antibody diluted to 1:100)
IHC-P analysis of human lung cancer tissue using CD133 antibody (Primary antibody diluted to 1:100)
Immunohistochemical analysis of formalin-fixed and paraffin embedded human colonic adenocarcinoma tissue using CD133 antibody (Dilution of primary antibody 1:100)
Immunohistochemical analysis of formalin-fixed and paraffin embedded human colonic adenocarcinoma tissue using CD133 antibody (Dilution of primary antibody 1:100)
IHC-P analysis of human muscle tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of human muscle tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of human colonic adenocarcinoma tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of human colonic adenocarcinoma tissue using CD133 antibody (Primary antibody at 1:100)
Immunohistochemical analysis of formalin-fixed and paraffin embedded human muscle tissue using CD133 antibody (Primary antibody diluted to 1:200)
Immunohistochemical analysis of formalin-fixed and paraffin embedded human muscle tissue using CD133 antibody (Primary antibody diluted to 1:200)
IHC-P analysis of human lung cancer tissue using CD133 antibody (Dilution of primary antibody 1:100)
IHC-P analysis of human lung cancer tissue using CD133 antibody (Dilution of primary antibody 1:100)
Immunohistochemical analysis of formalin-fixed and paraffin embedded mouse skin tissue using CD133 antibody (Dilution of primary antibody 1:100)
Immunohistochemical analysis of formalin-fixed and paraffin embedded mouse skin tissue using CD133 antibody (Dilution of primary antibody 1:100)
Immunofluorescent analysis of mouse brain tissue using CD133 antibody (Primary antibody diluted to 1:200)
Immunofluorescent analysis of mouse brain tissue using CD133 antibody (Primary antibody diluted to 1:200)
IHC-P analysis of mouse brain tissue using CD133 antibody (Dilution of primary antibody 1:100)
IHC-P analysis of mouse brain tissue using CD133 antibody (Dilution of primary antibody 1:100)
IHC-P analysis of mouse heart tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of mouse heart tissue using CD133 antibody (Primary antibody at 1:100)
Immunohistochemical staining of paraffin embedded human breast cancer tissue using anti-CD206 (primary antibody at 1:200)
Immunohistochemical staining of paraffin embedded human breast cancer tissue using anti-CD206 (primary antibody at 1:200)
IHC-P analysis of mouse liver tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of mouse liver tissue using CD133 antibody (Primary antibody at 1:100)
IHC-P analysis of mouse liver tissue using CD133 antibody (Dilution of primary antibody 1:100)
IHC-P analysis of mouse liver tissue using CD133 antibody (Dilution of primary antibody 1:100)
IF analysis analysis of mouse lung tissue using CD133 antibody (Dilution of primary antibody 1:200)
IF analysis analysis of mouse lung tissue using CD133 antibody (Dilution of primary antibody 1:200)
 Western Blot on human cells using CD133 antibody (Protocol steps under Review A) [Reviews]
Western Blot on human cells using CD133 antibody (Protocol steps under Review A) [Reviews]
WB analysis of rat small intestine tissue using CD133 antibody (dilution at 1:200-1:1000 based on 1mg/mL)
WB analysis of rat small intestine tissue using CD133 antibody (dilution at 1:200-1:1000 based on 1mg/mL)
Western blot analysis of human cancer cell lysates using CD133 antibody [Reviews]
Western blot analysis of human cancer cell lysates using CD133 antibody [Reviews]
IHC-P analysis of mouse heart tissue using CD133 antibody (Primary antibody diluted to 1:100)
IHC-P analysis of mouse heart tissue using CD133 antibody (Primary antibody diluted to 1:100)
 Immunohistochemical analysis of paraffin-embedded human mammary cancer tissue using CD133 antibody
Immunohistochemical analysis of paraffin-embedded human mammary cancer tissue using CD133 antibody
References

  1. Sun, Z. et al. Tumour stem cell markers CD133 and CD44 are useful prognostic factors after surgical resection of pancreatic neuroendocrine tumours. Oncol Lett 20, 341 (2020)
  2. Liao, C. H. et al. Restoration of erectile function with intracavernous injections of endothelial progenitor cells after bilateral cavernous nerve injury in rats. Andrology 3, 924-932 (2015)
  3. Tu, Z. et al. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer. Int. J. Oncol. 50, 505-514 (2017)
  4. Feng, L. et al. Isolation and phenotypic characterization of cancer stem-like side population cells in colon cancer. Mol Med Rep 12, 3531-3536 (2015)
  5. Kase, M. et al. Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme. Radiol Oncol 47, 405-410 (2013)
  6. Nel, I. et al. Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS ONE 11, e0153018 (2016)
  7. Yang, M. et al. An innovative three-dimensional gelatin foam culture system for improved study of glioblastoma stem cell behavior. J. Biomed. Mater. Res. Part B Appl. Biomater. 103, 618-628 (2015)
  8. Zou, Y. et al. Nrf2 is involved in maintaining hepatocyte identity during liver regeneration. PLoS ONE 9, e107423 (2014)
  9. Zhu, Y. et al. Influence of interferon-? on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Exp. Cell Res. 324, 146-156 (2014)
  10. Nowacki, M. et al. Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis. Oncotarget 6, 22776-22798 (2015)
  11. Nadal, R. et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int. J. Cancer 133, 2398-2407 (2013)
  12. Winardi, D. et al. Correlation of altered expression of the autophagy marker LC3B with poor prognosis in astrocytoma. Biomed Res Int 2014, 723176 (2014)
  13. Jensen, T. et al. Descriptive analysis of tumor cells with stem like phenotypes in metastatic and benign adrenal tumors. J. Pediatr. Surg. 50, 1493-1501 (2015)
  14. Hirashima, K. et al. Cell biological profiling of reprogrammed cancer stem cell-like colon cancer cells maintained in culture. Cell Tissue Res., (2018)

Reviews
Write Your Own Review
You're reviewing:CD133 antibody - orb99113
Your Rating